Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver Diseases

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle patent estate, announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.